Biomedical research at Oslo University Hospital

Publications (original articles or review articles) published in 2020 from OUS - Section for Lymphoma and Medicine

20 publications found

Autio M, Leivonen SK, Brück O, Mustjoki S, Jørgensen JM, Karjalainen-Lindsberg ML, Beiske K, Holte H, Pellinen T, Leppä S (2020)
Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma
Haematologica (in press)
DOI 10.3324/haematol.2019.243626, PubMed 32079690

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Wilsgaard T, Smeland KB, Kiserud CE (2020)
Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress
Bone Marrow Transplant
DOI 10.1038/s41409-020-01098-5, PubMed 33139869

Eskelund CW, Dimopoulos K, Kolstad A, Glimelius I, Räty R, Gjerdrum LMR, Sonnevi K, Josefsson P, Nilsson-Ehle H, Bentzen HHN, Fagerli UM, Kuittinen O, Haaber J, Niemann CU, Pedersen LB, Larsen MT, Geisler CH, Hutchings M, Jerkeman M, Grønbæk K (2020)
Detailed Long-Term Follow-Up of Patients Who Relapsed After the Nordic Mantle Cell Lymphoma Trials: MCL2 and MCL3
Hemasphere, 5 (1), e510
DOI 10.1097/HS9.0000000000000510, PubMed 33364550

Fajgenbaum DC, Wu D, Goodman A, Wong R, Chadburn A, Nasta S, Srkalovic G, Mukherjee S, Leitch H, Jayanthan R, Ferrero S, Sato Y, Schey S, Dispenzieri A, Oksenhendler E, Zinzani PL, Lechowicz MJ, Hoffmann C, Pemmaraju N, Bagg A, Fossa A, Lim MS, van Rhee F, Castleman Disease Collaborative Network Scientific Advisory Board diagnostic criteria international working group and treatment guidelines international working group (2020)
Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease
Am J Hematol, 95 (12), 1553-1561
DOI 10.1002/ajh.25992, PubMed 32894785

Fosså A, Smeland KH, Fluge Ø, Tronstad KJ, Loge JH, Midttun Ø, Ueland PM, Kiserud CE (2020)
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue
PLoS One, 15 (1), e0227384
DOI 10.1371/journal.pone.0227384, PubMed 31923274

Hannevik TL, Brekke J, Enden T, Frøen H, Garresori H, Jacobsen EM, Paulsen PQ, Porojnicu AC, Ree AH, Torfoss D, Velle EO, Wik HS, Ghanima W, Sandset PM, Dahm AEA (2020)
Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolism
Thromb Res, 196, 238-244
DOI 10.1016/j.thromres.2020.08.042, PubMed 32919178

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Kimby E, Lockmer S, Holte H, Hagberg H, Wahlin BE, Brown P, Østenstad B (2020)
The simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
Br J Haematol, 191 (5), 738-747
DOI 10.1111/bjh.16692, PubMed 32410260

Kluge R, Wittig T, Georgi TW, Kurch L, Sabri O, Wallace WH, Klekawka T, Fernández-Teijeiro A, Ceppi F, Karlén J, Pears J, Cepelová M, Fosså A, Beishuizen A, Hjalgrim LL, Körholz D, Mauz-Körholz C, Hasenclever D (2020)
Comparison of Interim PET Response to Second-Line Versus First-Line Treatment in Classic Hodgkin Lymphoma: Contribution to the Development of Response Criteria for Relapsed or Progressive Disease
J Nucl Med, 62 (3), 338-341
DOI 10.2967/jnumed.120.247924, PubMed 32764122

Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, Blakkisrud J, Løndalen A, O'Rourke N, Beasley M, Jurczak W, Fagerli UM, Kaščák M, Bayne M, Obr A, Dahle J, Rojkjaer L, Pascal V, Holte H (2020)
Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma
Blood Adv, 4 (17), 4091-4101
DOI 10.1182/bloodadvances.2020002583, PubMed 32877524

Leppä S, Jørgensen J, Tierens A, Meriranta L, Østlie I, de Nully Brown P, Fagerli UM, Larsen TS, Mannisto S, Munksgaard L, Maisenhölder M, Vasala K, Meyer P, Jerkeman M, Björkholm M, Fluge Ø, Jyrkkiö S, Liestøl K, Ralfkiaer E, Spetalen S, Beiske K, Karjalainen-Lindsberg ML, Holte H (2020)
Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis
Blood Adv, 4 (9), 1906-1915
DOI 10.1182/bloodadvances.2020001518, PubMed 32380536

Lokhande L, Kuci Emruli V, Kolstad A, Hutchings M, Räty R, Jerkeman M, Ek S (2020)
Immune-related protein signature in serum stratify relapsed mantle cell lymphoma patients based on risk
BMC Cancer, 20 (1), 1202
DOI 10.1186/s12885-020-07678-4, PubMed 33287742

Løndalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A, Stokke C (2020)
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of ¹⁷⁷Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma
Eur J Nucl Med Mol Imaging
DOI 10.1007/s00259-020-05098-x, PubMed 33196921

Maaland AF, Saidi A, Torgue J, Heyerdahl H, Stallons TAR, Kolstad A, Dahle J (2020)
Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003
PLoS One, 15 (3), e0230526
DOI 10.1371/journal.pone.0230526, PubMed 32187209

Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS (2020)
Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma
Blood Adv, 4 (4), 629-637
DOI 10.1182/bloodadvances.2019001026, PubMed 32074277

Pierson SK, Khor JS, Ziglar J, Liu A, Floess K, NaPier E, Gorzewski AM, Tamakloe MA, Powers V, Akhter F, Haljasmaa E, Jayanthan R, Rubenstein A, Repasky M, Elenitoba-Johnson K, Ruth J, Jacobs B, Streetly M, Angenendt L, Patier JL, Ferrero S, Zinzani PL, Terriou L, Casper C, Jaffe E et al. (2020)
ACCELERATE: A Patient-Powered Natural History Study Design Enabling Clinical and Therapeutic Discoveries in a Rare Disorder
Cell Rep Med, 1 (9), 100158
DOI 10.1016/j.xcrm.2020.100158, PubMed 33377129

Rekeland IG, Fosså A, Lande A, Ktoridou-Valen I, Sørland K, Holsen M, Tronstad KJ, Risa K, Alme K, Viken MK, Lie BA, Dahl O, Mella O, Fluge Ø (2020)
Intravenous Cyclophosphamide in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. An Open-Label Phase II Study
Front Med (Lausanne), 7, 162
DOI 10.3389/fmed.2020.00162, PubMed 32411717

Rodrigues JM, Hassan M, Freiburghaus C, Eskelund CW, Geisler C, Räty R, Kolstad A, Sundström C, Glimelius I, Grønbaek K, Kwiecinska A, Porwit A, Jerkeman M, Ek S (2020)
p53 is associated with high-risk and pinpoints TP53 missense mutations in mantle cell lymphoma
Br J Haematol, 191 (5), 796-805
DOI 10.1111/bjh.17023, PubMed 32748433

van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R et al. (2020)
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease
Blood Adv, 4 (23), 6039-6050
DOI 10.1182/bloodadvances.2020003334, PubMed 33284946

Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
Blood Adv, 4 (9), 1859-1866
DOI 10.1182/bloodadvances.2019001325, PubMed 32374878